ASC30 vs ecnoglutide
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Obesity
Shared mechanism: GLP-1 receptor · full Obesity pipeline
ASC30
Developed by Ascletis Pharma
NCT07002905 · Phase 2 · completed
The study randomly assigned 125 participants and used quadruple blinding with placebo control across seven cohorts. Its primary endpoint was percent change in body weight at Week 13, but the registry has not posted whether this endpoint was met.
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
Next expected readout: July 2028 · NCT07743463 (registry estimate)
Reported efficacy
Percent change in body weight from Baseline up to Week 13 (Baseline and Week 13): Placebo-adjusted mean weight loss at Week 13: 5.4% (20mg), 7.0% (40mg), 7.7% (60mg) ASC30, all p<0.0001 vs placebo (met)
Result source: NCT07002905
ecnoglutide
Marketed by Pfizer under a licence from Sciwind Biosciences
NCT05813795 · Phase 3 · completed
SLIMMER was a randomized, double-blind, placebo-controlled Phase 3 trial at 36 centres in China. It assigned 664 adults with overweight or obesity and without diabetes to once-weekly ecnoglutide 1.2 mg, 1.8 mg or 2.4 mg or placebo. The two primary endpoints at week 40 were the percent change in body weight and the proportion of participants who lost at least 5% of their body weight. All three doses were significantly better than placebo on both endpoints (all p<0.0001), so the trial met its primary endpoints. The figures come from the peer-reviewed paper in The Lancet Diabetes and Endocrinology.
Next expected readout: February 2027 · NCT07073417 (registry estimate)
Reported efficacy
Co-primary: percent change in body weight from baseline to week 40, and proportion of participants with at least 5% body-weight reduction at week 40: Co-primary 1, percent change in body weight from baseline to week 40 (treatment-policy estimand): ecnoglutide 1.2 mg -9.1%, 1.8 mg -10.9%, 2.4 mg -13.2% vs placebo +0.1%; treatment differences -9.2% (97% CI -11.0 to -7.5), -11.1% (-13.1 to -9.1) and -13.3% (-15.3 to -11.3); all p<0.0001, met. Co-primary 2, weight reduction of at least 5% at week 40: 77%, 84% and 87% vs 16%; differences 60% (98% CI 50 to 71), 68% (58 to 78) and 70% (61 to 80); all p<0.0001, met. (met)
Result source: NCT05813795
Results for Obesity
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | ASC30 | ecnoglutide |
|---|---|---|
| Body weight, % change | —Trial running · NCT07743463 | -13.2% vs 0.1%a−13.3 vs placeboNCT05813795 |
| Weight loss of 5% or more | —Trial running · NCT07743463 | —Not posted · NCT05813795 |
| Weight loss of 10% or more | —Trial running · NCT07743463 | —Not posted · NCT05813795 |
| Waist circumference, change (cm) | —Trial running · NCT07743463 | —Not posted · NCT05813795 |
Body weight, % change
- ASC30
- —Trial running · NCT07743463
- ecnoglutide
- -13.2% vs 0.1%a−13.3 vs placeboNCT05813795
Weight loss of 5% or more
- ASC30
- —Trial running · NCT07743463
- ecnoglutide
- —Not posted · NCT05813795
Weight loss of 10% or more
- ASC30
- —Trial running · NCT07743463
- ecnoglutide
- —Not posted · NCT05813795
Waist circumference, change (cm)
- ASC30
- —Trial running · NCT07743463
- ecnoglutide
- —Not posted · NCT05813795
- a From a reviewed publication or company release; CT.gov has no posted result for this endpoint.
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
ASC30
show 2 more results
ecnoglutide
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: ASC30's landscape · ecnoglutide's landscape